You are here

  • Home
  • Archive
  • Volume 71, Issue 12
  • Clinical efficacy of leflunomide in primary Sjögren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Clinical efficacy of leflunomide in primary Sjögren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression

Authors

  1. Correspondence to Dr J A G van Roon, Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Heidelberlaan 100, F02.127, Utrecht 3584 CX, The Netherlands; J.vanRoon{at}umcutrecht.nl
View Full Text

Citation

Bikker A, van Woerkom J, Kruize AA, et al
Clinical efficacy of leflunomide in primary Sjögren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression
Annals of the Rheumatic Diseases 2012;71:1934-1941.

Publication history

  • Accepted March 23, 2012
  • First published May 6, 2012.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions